International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 1 , Pages 38-46 , 1 January 2006

Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy

  • Dong Wook Kim, M.D., Ph.D.
    • ,
  • Jessica Huamani, M.S.
    • ,
  • Allie Fu, B.S.
    • ,
  • Dennis E. Hallahan, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Dennis E. Hallahan, M.D., Vanderbilt University Medical Center, Department of Radiation Oncology, B-902, 1301 22nd Avenue South, Nashville, TN 37232-5671. Tel: (615) 343-9244; Fax: (615) 343-3075

Received 4 January 2005 ,Revised 8 February 2005 ,Accepted 8 February 2005.

References 

  1. De Vita VT , Hellman S , Rosenberg SA . In: 6th ed.. Cancer. Principles and practice of oncology . Vol 1: Philadelphia: Lippincott Williams & Wilkins; 2001;
  2. Fuks Z , Vlodavsky I , Andreeff M , et al.   Effects of extracellular matrix on the response of endothelial cells to radiation in vitro . Eur J Cancer . 1992;28A:725–731
  3. Garcia-Barros M , Paris F , Cordon-Cardo C , et al.   Tumor response to radiotherapy regulated by endothelial cell apoptosis . Science . 2003;300:1155–1159
  4. Paris F , Fuks Z , Kang A , et al.   Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice . Science . 2001;293:293–297
  5. Wachsberger P , Burd R , Dicker AP . Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents (Exploring mechanisms of interaction) . Clin Cancer Res . 2003;9:1957–1971
  6. Wachsberger P , Burd R , Dicker AP . Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways . Hematol Oncol Clin North Am . 2004;18:1039–1057 viii
  7. Mauceri HJ , Hanna NN , Beckett MA , et al.   Combined effects of angiostatin and ionizing radiation in antitumour therapy . Nature . 1998;394:287–291
  8. Gorski DH , Beckett MA , Jaskowiak NT , et al.   Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation . Cancer Res . 1999;59:3374–3378
  9. Tan J , Hallahan DE . Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response . Cancer Res . 2003;63:7663–7667
  10. Edwards E , Geng L , Tan J , et al.   Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation . Cancer Res . 2002;62:4671–4677
  11. Geng L , Donnelly E , McMahon G , et al.   Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy . Cancer Res . 2001;61:2413–2419
  12. Geng L , Tan J , Himmelfarb E , et al.   A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3′-kinase, IC486068, enhances radiation-induced tumor vascular destruction . Cancer Res . 2004;64:4893–4899
  13. Schueneman AJ , Himmelfarb E , Geng L , et al.   SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models . Cancer Res . 2003;63:4009–4016
  14. Datta K , Bellacosa A , Chan TO , et al.   Akt is a direct target of the phosphatidylinositol 3-kinase (Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells) . J Biol Chem . 1996;271:30835–30839
  15. Vanhaesebroeck B , Alessi DR . The PI3K-PDK1 connection (More than just a road to PKB) . Biochem J . 2000;346:561–576
  16. Alessi DR , James SR , Downes CP , et al.   Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha . Curr Biol . 1997;7:261–269
  17. Contessa JN , Hampton J , Lammering G , et al.   Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells . Oncogene . 2002;21:4032–4041
  18. Stein RC . Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment . Endocr Relat Cancer . 2001;8:237–248
  19. Hiles ID , Otsu M , Volinia S , et al.   Phosphatidylinositol 3-kinase (Structure and expression of the 110 kd catalytic subunit) . Cell . 1992;70:419–429
  20. Klippel A , Escobedo JA , Hu Q , et al.   A region of the 85-kilodalton (kDa) subunit of phosphatidylinositol 3-kinase binds the 110-kDa catalytic subunit in vivo . Mol Cell Biol . 1993;13:5560–5566
  21. Klippel A , Escobedo JA , Hirano M , et al.   The interaction of small domains between the subunits of phosphatidylinositol 3-kinase determines enzyme activity . Mol Cell Biol . 1994;14:2675–2685
  22. Stern DF . Tyrosine kinase signalling in breast cancer (ErbB family receptor tyrosine kinases) . Breast Cancer Res . 2000;2:176–183
  23. Neve RM , Sutterluty H , Pullen N , et al.   Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells . Oncogene . 2000;19:1647–1656
  24. Altiok N , Altiok S , Changeux JP . Heregulin-stimulated acetylcholine receptor gene expression in muscle (Requirement for MAP kinase and evidence for a parallel inhibitory pathway independent of electrical activity) . Embo J . 1997;16:717–725
  25. Downward J . Lipid-regulated kinases (Some common themes at last) . Science . 1998;279:673–674
  26. Alessi DR , Andjelkovic M , Caudwell B , et al.   Mechanism of activation of protein kinase B by insulin and IGF-1 . Embo J . 1996;15:6541–6551
  27. Wymann MP , Pirola L . Structure and function of phosphoinositide 3-kinases . Biochim Biophys Acta . 1998;1436:127–150
  28. Vivanco I , Sawyers CL . The phosphatidylinositol 3-kinase AKT pathway in human cancer . Nat Rev Cancer . 2002;2:489–501
  29. Dudek H , Datta SR , Franke TF , et al.   Regulation of neuronal survival by the serine-threonine protein kinase Akt . Science . 1997;275:661–665
  30. Datta SR , Dudek H , Tao X , et al.   Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery . Cell . 1997;91:231–241
  31. Zingg D , Riesterer O , Fabbro D , et al.   Differential activation of the phosphatidylinositol 3′-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells . Cancer Res . 2004;64:5398–5406
  32. Kim DW , Lu B , Hallahan DE . Receptor tyrosine kinase inhibitors as anti-angiogenic agents . Curr Opin Investig Drugs . 2004;5:597–604
  33. Prewett M , Huber J , Li Y , et al.   Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors . Cancer Res . 1999;59:5209–5218
  34. Dunn IF , Heese O , Black PM . Growth factors in glioma angiogenesis (FGFs, PDGF, EGF, and TGFs) . J Neurooncol . 2000;50:121–137
  35. Fuks Z , Persaud RS , Alfieri A , et al.   Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo . Cancer Res . 1994;54:2582–2590
  36. Seghezzi G , Patel S , Ren CJ , et al.   Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries (An autocrine mechanism contributing to angiogenesis) . J Cell Biol . 1998;141:1659–1673
  37. Tsai JC , Goldman CK , Gillespie GY . Vascular endothelial growth factor in human glioma cell lines (Induced secretion by EGF, PDGF-BB, and bFGF) . J Neurosurg . 1995;82:864–873
  38. Witte L , Fuks Z , Haimovitz-Friedman A , et al.   Effects of irradiation on the release of growth factors from cultured bovine, porcine, and human endothelial cells . Cancer Res . 1989;49:5066–5072
  39. Schlessinger J . Cell signaling by receptor tyrosine kinases . Cell . 2000;103:211–225
  40. Claesson-Welsh L . Signal transduction by the PDGF receptors . Prog Growth Factor Res . 1994;5:37–54
  41. Claesson-Welsh L . Platelet-derived growth factor receptor signals . J Biol Chem . 1994;269:32023–32026
  42. Kim DW , Choy H . Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer . Int J Radiat Oncol Biol Phys . 2004;59:11–20
  43. Kozin SV , Boucher Y , Hicklin DJ , et al.   Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts . Cancer Res . 2001;61:39–44
  44. Abdollahi A , Lipson KE , Han X , et al.   SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro . Cancer Res . 2003;63:3755–3763
  45. Bischof M , Abdollahi A , Gong P , et al.   Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells . Int J Radiat Oncol Biol Phys . 2004;60:1220–1232
  46. Hurwitz H , Fehrenbacher L , Novotny W , et al.   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med . 2004;350:2335–2342
  47. Crane CH , Ellis LM , O’Reilly MS , et al.   RhuMab VEGF (Bevacizumab) with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer (An active, well tolerated regimen) . Int J Radiat Oncol Biol Phys . 2004;60(Suppl. 1):S149
  48. Wood JM , Bold G , Buchdunger E , et al.   PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration . Cancer Res . 2000;60:2178–2189
  49. Hess C , Vuong V , Hegyi I , et al.   Effect of VEGF receptor inhibitor PTK787/ZK222584 combined with ionizing radiation on endothelial cells and tumour growth . Br J Cancer . 2001;85:2010–2016
  50. Laird AD , Christensen JG , Li G , et al.   SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice . Faseb J . 2002;16:681–690
  51. Laird AD , Vajkoczy P , Shawver LK , et al.   SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors . Cancer Res . 2000;60:4152–4160
  52. Griffin RJ , Williams BW , Wild R , et al.   Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response . Cancer Res . 2002;62:1702–1706
  53. Lu B , Geng L , Musiek A , et al.   Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium . Int J Radiat Oncol Biol Phys . 2004;58:844–850
  54. Mendel DB , Laird AD , Xin X , et al.   In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors (Determination of a pharmacokinetic/pharmacodynamic relationship) . Clin Cancer Res . 2003;9:327–337
  55. Gupta AK , Cerniglia GJ , Mick R , et al.   Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002 . Int J Radiat Oncol Biol Phys . 2003;56:846–853
  56. Sarkaria JN , Tibbetts RS , Busby EC , et al.   Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin . Cancer Res . 1998;58:4375–4382
  57. Rosenzweig KE , Youmell MB , Palayoor ST , et al.   Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay . Clin Cancer Res . 1997;3:1149–1156
  58. Price BD , Youmell MB . The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage . Cancer Res . 1996;56:246–250
  59. Sadhu C, Dick K, Treiberg J. Inhibitors of human phosphatidylinositol 3-kinase delta. US Patent Application 20020161014 2002;WO 01/81346.
  60. Chan S . Targeting the mammalian target of rapamycin (mTOR) (A new approach to treating cancer) . Br J Cancer . 2004;91:1420–1424
  61. Boehm T , Folkman J , Browder T , et al.   Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance . Nature . 1997;390:404–407
  62. Arap W , Pasqualini R , Ruoslahti E . Chemotherapy targeted to tumor vasculature . Curr Opin Oncol . 1998;10:560–565
  63. Arap W , Pasqualini R , Ruoslahti E . Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model . Science . 1998;279:377–380
  64. Pasqualini R , Koivunen E , Ruoslahti E . Alpha v integrins as receptors for tumor targeting by circulating ligands . Nat Biotechnol . 1997;15:542–546
  65. Hallahan D , Geng L , Qu S , et al.   Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels . Cancer Cell . 2003;3:63–74
  66. Hallahan DE , Geng L , Cmelak AJ , et al.   Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature . J Control Release . 2001;74:183–191
  67. Camphausen K , Moses MA , Menard C , et al.   Radiation abscopal antitumor effect is mediated through p53 . Cancer Res . 2003;63:1990–1993
  68. Geng L , Osusky K , Konjeti S , et al.   Radiation-guided drug delivery to tumor blood vessels results in improved tumor growth delay . J Control Release . 2004;99:369–381

PII: S0360-3016(05)00292-0

doi: 10.1016/j.ijrobp.2005.02.008

International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 1 , Pages 38-46 , 1 January 2006

Article Tools

* Image Usage & Resolution